Abstract: Objectives: The study was aimed at establishing an effective molecular-genetic method for detecting polymorphisms in genes CYP2C9 and VKORC1, which affect the pharmacogenetics of warfarin, and at determining their prevalence in Slovak population. Background: Warfarin, derivative of coumarin, belongs to the most commonly prescribed oral anticoagulants with narrow therapeutic index. An insuffi cient dose of warfarin can result in failure to produce the antithrombotic effect, whereas an overdose increases the risk of bleeding. It was proven that genetic variability in two genes, CYP2C9 a VKORC1, has a signifi cant infl uence on the individual's response to the dosage of warfarin. Methods: In a control group of 112 randomly selected individuals, we tested the frequency of selected single nucleotide polymorphisms including CYP2C9*2 (430C>T), CYP2C9*3 (1075A>C), VKORC1*2 (1173C>T) by allele-specifi c Real-Time PCR and VKORC1*2 (-1639G>A) by using PCR-RFLP. Results: Due to the combination of frequent alleles CYP2C9*2, CYP2C9*3 and VKORC1*2 in Slovak population we determine that 25% of population need a standard 5-mg daily dose of warfarin, while 44%, 23%, and 8% need 4 mg, 3 mg and 2 mg of warfarin per day. Conclusion: Slovak population is in Hardy-Weinberg equilibrium and frequencies of SNPs were in accordance with other published results in European populations (Tab. 5. Fig. 3, Ref. 51). Text in PDF www.elis.sk.
Warfarin as well as other 4-hydroxycoumarin derivates is used as an oral anticoagulant. It functions as an antagonist of vitamin K, which is a necessary factor of the blood clotting cascade (1) . Nowadays it is one of the drugs most commonly used in prevention or therapy of some disorders. High risk of embolisms, heart attack, atrial fi brillation, some of inherited blood coagulation diseases, and conditions after surgery (e.g. heart valve) are treated with warfarin. Also, it is used as a prevention treatment in patients at high risk of stroke or in relapse of deep vein thrombosis (2) . The essential anticoagulant effect of warfarin is induced by the inhibition of vitamin K epoxide reductase (VKOR), which leads to a decrease in vitamin K-dependent coagulation protein synthesis (3) . The commercially used warfarin is a racemic mixture of S-and R-enantiomers. These isoforms have mutually different metabolic effects. S-warfarin is about fi ve times more active than R-warfarin (4) . After oral intake, warfarin is transported to the liver, where R enantiomer is metabolized by cytochromes (CYP1A1, CYP1A2 and CYP3A4) and more effective S enantiomer is metabolized by cytochrome P450 (CYP2C9) (5) . Gamma-glutamyl carboxylase (GGCX) participates in the activation of the hypofunctional prothrombin clotting factors II, VII, IX, X to its active form (6) . A reduced form of vitamin K infl uenced by VKOR takes part in the clotting process (Fig. 1) . VKOR infl uences both warfarin enantiomers, which leads into a decrease in their effi ciency (7) .
The enzyme activity affecting the metabolism of warfarin can be expressed at different phenotypes levels, usually called as NM -normal metabolizers, IM -intermediate metabolizers, and PM -poor metabolizers. The time required to achieve stable concentration of warfarin in serum varies also in dependence on the genotype of each patients (8) .
According to up-to-date knowledge, warfarin metabolism is mainly infl uenced by genetic factors such as polymorphisms affecting CYP2C9 enzyme activity and pharmacokinetics (4) and pharmacodynamics of VKORC1 (9) .
CYP2C9 is located on chromosome 10 and consists of 9 exons and 8 introns. The CYP2C9 gene is highly polymorphic. Two allelic variants, CYP2C9*2 (430C>T, rs1799853) and CYP2C9*3 (1075A>C, rs1057910) differing from the wild-type CYP2C9*1 by a single point mutation, have been associated with reduced metabolic clearance of CYP2C9 substrates (such as warfarin and phenytoin) as compared to the wild-type. Thus a standard dose may result in raised serum drug levels (10). CYP2C9*2 is located in exon 3 and the incidence of allele T in Caucasians is 10-20 %. CYP2C9*3 is located in exon 7 and the incidence of allele C in Caucasians is 8 % (11). Both of these allelic variants are less frequent in Asian and Afro-American people (12) . Polymorphic forms of enzymes lead to a decrease in hydroxylation of S-warfarin in vitro and patients with this genotype belong to the PM phenotype. In the early stages of therapy, PM phenotypes are at risk of increased bleeding after warfarin treatment. These individuals require lower doses of warfarin to achieve the desired anticoagulant effect compared to patients with at least one CYP2C9*1 (WT) haplotype (13) . The enzyme activity is reduced to 12 % (CYP2C9*2) and 5 % (CYP2C9*3), respectively to WT (14) . Studies show that CYP2C9 genotype is responsible for 12 % of interindividual variability in response to warfarin therapy (12) .
VKORC1 is located on chromosome 16 and consists of 3 exons and 2 introns (1). Common polymorphisms in the regulatory region of VKORC1 gene correlate strongly with warfarin response across the normal dosing range (15) . Polymorphisms in VKORC1 gene signifi cantly change the pharmacodynamics and dosage adequacy of warfarin (16) . The most frequent and most deeply studied polymorphisms are VKORC1 -1639G>A and 1173C>T. These SNPs, in the promotor and fi rst intron of VKORC1 gene infl uence the enzymatic activity of VKOR (17) which is an enzyme in vitamin K cycles and the pharmacological target of coumarins (18) . VKORC1 1173C>T, rs9934438 is in almost complete linkage disequilibrium with the polymorphism of VKORC1 -1639G>A, rs9923231 where both associate with increased sensitivity to warfarin (16) . These SNPs are responsible for 30 % of interindividual variability in warfarin treatment (7) . Haplotype VKORC1*2 is present in 42 % of Europeans (19) and is relatively rare in Asian population (20) .
The management of warfarin therapy is challenging because on the one hand there is a large variability in dose requirements (0.5-60 mg per day) necessary for effective therapy and on the other hand there is the risk of life-threatening bleeding (21). The range of warfarin doses for individual genotypes is based on numerous conducted studies. To determine the warfarin dose, we have to take into account age, race, weight, height, sex, other medications, as well as polymorphisms in genes CYP2C9 and VKORC1 (22). The prediction of dosing based on genotypes is presented in Table 1 (23).
Material and methods
The control group consists of 112 individuals, all healthy subjects of Caucasian origin. Participants signed an informed consent before the study. They were randomly selected and never treated with warfarin. Blood samples for DNA extraction were collected in 3-mL tubes containing potassium EDTA. DNA was extracted from 200 μl whole blood by using DNA NucleoSpin Blood Kit (Macherey-Nagel). The frequencies of selected single nucleotide polymorphisms CYP2C9*2 (430C>T), CYP2C9*3 (1075A>C), VKORC1*2 (1173C>T) were tested in a control group (112 randomly selected individuals) by allele-specifi c Real-Time PCR. The reaction was performed in 10-μl volumes containing approximately 100 ng of DNA. The assay for identifi cation of CYP2C9 and VKORC1 alleles were obtained from Applied Biosystems: C__25625805_10 for CYP2C9*2 (430C>T) rs1799853, C__27104892_10 for CYP2C9*3 (1075A>C) rs1057910 and C__30204875_10 for VKORC1*2 (1173C>T) rs9934438. The amplifi cation of PCR consisted of an initial denaturation step at 95 °C for 10 min followed by 45 amplifi cation cycles (95 °C for 15 sec and 60 °C for 60 sec). The frequencies of SNP VKORC1*2
(-1639G>A) rs9923231was tested in a control group (112 randomly selected individuals) by using PCR-RFLP. The PCR reaction was performed in 20 μl volumes containing approximately 100 ng of DNA, 2xPCR Master Mix (Fermantas), 0.5 μM of each primer (Forward 5´ GCCAGCAGGAGAGGGAAATA 3´ and Rewerse 5´AGTTTGGACTACAGGTGCCT 3´). The amplifi cation of PCR consisted of an initial denaturation step at 95 °C for 2 min followed by 35 amplifi cation cycles (95 °C for 15 sec, 59 °C for 30 sec, 72 °C for 60 sec) and fi nal polymerization step at 72 °C for 7 min. After PCR reaction, all PCR products were digested by restriction enzyme HpaII (Fermentas) which cuts when -1639G>A polymorphisms is not present, and visualized by agarose gel electrophoresis.
To fi nd out if the Slovak population is in to the Hardy-Weinberg equilibrium the results were evaluated by chi-square test. Allele's frequencies of different populations were determined and compared using Z-test.
Results
We determine the genotypes of CYP2C9*2 (430C>T) rs1799853, CYP2C9*3 (1075A>C) rs1057910 and VKORC1*2 (1173C>T) rs9934438 by allele-specifi c Real-Time PCR (Fig 2) and VKORC1*2 (-1639G>A) rs9923231 by PCR-RFLP (Fig. 3) . The frequency rate of selected polymorphisms in genes CYP2C9 and VKORC1 infl uencing the pharmacogenetics of warfarin was tested in the control group of 112 randomly selected individuals. The range of expected warfarin dosage based only on polymorphisms in genes CYP2C9 (CYP2C9*2, 430C>T, rs1799853 and CYP2C9*3, 1075A>C, rs1057910) and VKORC1 (VKORC1*2, -1639G>A, rs9923231) and their combination (23). To determine the warfarin dose, we have to take into account age, race, weight, height, sex and other medications.
Tab. 1. Infl uence of genotype effect on warfarin dose per day.
Fig. 2. Schematic pictures of Allele-specifi c Real-Time PCR of polymorphisms in genes CYP2C9 (430C>T, rs1799853 and 1075A>C, rs1057910) and VKORC1 (1173C>T, rs9934438) (a -Wild-type allele, b -mutant allele).
A -Wild type B -Heterozygous C -Mutant We defi ned the haplotypes (Tab. 2) and genotypes (Tab. 3) frequencies. To detect signifi cant differences in the frequency of alleles between Slovak and other populations (Tabs 4 and 5) we used a statistical test method Z.
Discussion
The implementation of molecular-genetic diagnostic methods in pharmacology has brought forward the fact that the drugs with a narrow therapeutic index are now safer for setting up a proper dose in view of individual genome variations and individualized therapy. Warfarin belongs to this group of drugs, and their effect is infl uenced by polymorphisms in genes CYP2C9 and VKORC1. Detection of genotype before initiating the therapy could help avoid complications right at the beginning but also during longterm treatment.
It is estimated that seven million people are treated with warfarin worldwide. In Europe, it is approximately two million patients. However, more than 20 % of them are hospitalized in the fi rst six months because of bleeding complications caused by anticoagulant treatment (9) . The pharmacogenetics of warfarin is signifi cantly infl uenced by genetic factors such as the prevalence of polymorphisms in genes CYP2C9 and VKORC1. We determined the SNPs genotype CYP2C9*2, CYP2C9*3 and VKORC1*2 of 112 individuals by using allele-specifi c RealTime PCR and PCR-RFLP. Frequencies of alleles with polymorphisms found in the current study are 10 % (CYP2C9*2), 8 % (CYP2C9*3) and 38 % (VKORC1*2). Similar results were described by Takahashi et al 2006 (24) , who determined the frequency of the same alleles was 14 %, 11 % and 42 % in 115 subjects of Caucasian population. Polymorphisms in genes CYP2C9 and VKORC1 play an important role in the dosage of warfarin. Based on the results mentioned above, 25 % of Slovak population was found to need a standard dose of warfarin (5 mg per day). Taking into account a combination of the most severe polymorphisms CYP2C9*2, CYP2C9*3 and VKORC1*2, 44 %, 23 % and 8 % of individuals need 4 mg, 3 mg and 2 mg of warfarin per day, respectively based on the general therapeutic scheme implemented by Kitzmiller et al 2011 (23) . Despite large advances in the prediction of stable warfarin dose, approximately 50 % of the dose variability remains unexplained. Inter-and intraindividual variability is a big challenge in warfarin treatment. The anticoagulant effects of warfarin are modifi ed also by diet and foods containing vitamin K, although the dietary infl uences tend to be of more short-term character (25) . VKORC1*3 haplotype (3730G>A, rs7294) was also defi ned and is present in 38 % of Europeans (13) . It causes an increase in the dosage of warfarin (AA) up to 30 % compared with WT (7). The frequency of this allele in the Slovak population is 41 % (26) .
Slovak population is in Hardy-Weinberg equilibrium. The frequencies of selected SNPs correlate with other European populations (7, 22, 33, 35, 36, 38, 42) and thus with Caucasians (17) . This type of study was done for the fi rst time in Slovakia.
Knowledge of the genotype of individuals allows physicians to adequately set up the warfarin dosage and avoid undesirable complications and life-threatening conditions, especially at the beginning of the warfarin therapy. The pharmacogenetic test is useful also for patients who are treated with warfarin in long term and suffer from serious side effects. FDA (Food and Drug Association) recommends genotype testing before the start of therapy.
